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Abstract
Most of the existing medicine recommendation systems that
are mainly based on electronic medical records (EMRs) are
significantly assisting doctors to make better clinical deci-
sions benefiting both patients and caregivers. Even though
the growth of EMRs is at a lighting fast speed in the era
of big data, content limitations in EMRs restrain the existed
recommendation systems to reflect relevant medical facts,
such as drug-drug interactions. Many medical knowledge
graphs that contain drug-related information, such as Drug-
Bank, may give hope for the recommendation systems. How-
ever, the direct use of these knowledge graphs in the sys-
tems suffers from robustness caused by the incompleteness
of the graphs. To address these challenges, we stand on re-
cent advances in graph embedding learning techniques and
propose a novel framework, called Safe Medicine Recom-
mendation (SMR), in this paper. Specifically, SMR first con-
structs a high-quality heterogeneous graph by bridging EMRs
(MIMIC-III) and medical knowledge graphs (ICD-9 ontol-
ogy and DrugBank). Then, SMR jointly embeds diseases,
medicines, patients, and their corresponding relations into a
shared lower dimensional space. Finally, SMR uses the em-
beddings to decompose the medicine recommendation into
a link prediction process while considering the patient’s di-
agnoses and adverse drug reactions. To our best knowledge,
SMR is the first to learn embeddings of a patient-disease-
medicine graph for medicine recommendation in the world.
Extensive experiments on real datasets are conducted to eval-
uate the effectiveness of proposed framework.
1 Introduction
Over the last few years, medicine recommendation sys-
tems have been developed to assist doctors in making ac-
curate medicine prescriptions. On the one hand, many re-
searchers (Chen et al. 2016; Almirall et al. 2012) adopt
rule-based protocols that are defined by the clinical guide-
lines and the experienced doctors. Constructing, curating,
and maintaining these protocols are time-consuming and
labor-intensive. Rule-based protocols might be effective for
a general medicine recommendation for a specific diagnosis,
but give little help to tailored recommendations for compli-
cated patients. On the other hand, supervised learning al-
gorithms and variations, such as Multi-Instance Multi-label
(MIML) learning (Zhang et al. 2017), have been proposed to
recommend medicines for patients. Both input features and
ground-truth information that are extracted from massive
EMRs are trained to obtain a predictive model that outputs
multiple labels of the new testing data as medicine recom-
mendations. It is a fact that therapies and treatments in clin-
ical practices are rapidly updated. Unfortunately, supervised
learning methods cannot deal with those medicines that are
not included in the training phase. Incomplete training data
set will be a detriment to the recommendation system per-
formance.
It is reported in (Panagioti et al. 2015; Juurlink et al.
2003) that patients with two or more diseases, acute or
chronic, often take five or more different medicines simul-
taneously and have immense health risks. Studies (Edwards
and Aronson 2000; Leape et al. 1995) have shown that 3-
5% of all in-hospital misused prescriptions blame to igno-
rances of adverse drug reactions, which is difficult to pro-
hibit even for the highly trained and experienced clinicians.
With the assistance from the conventional medicine recom-
mendation systems, clinicians still need to cautiously rule
out those recommendations that have potential adverse ef-
fects caused by drug-drug interactions. Most of the existing
works have largely ignored the exploit of medical facts in
medicines, such as drug-drug interactions, which is crucial
in medicine recommendation system. One possible reason
might because there is little medical expert knowledge in
EMRs. Content limitations in EMRs constrain the systems
to barely associate accurate medical facts with the recom-
mended prescriptions, which makes the final recommenda-
tion less trustworthy for the complicated patients.
With the increasing emergence of knowledge graphs,
many world-leading researchers have successfully extracted
information from huge volumes of medical databases to
build up giant heterogeneous graphs that reflect medical
facts of medicines and diseases. For instance, DrugBank
(Law et al. 2014) is a rich source of medicine information.
It contains extensive entities (drugs, drug targets, chemistry,
etc.) and relationships (enzymatic pathways, drug-drug in-
teractions, etc.). ICD-9 ontology (Schriml et al. 2011) repre-
sents a knowledge base of human diseases and can be used
to classify diagnoses of patients. Harnessing well-built med-
ical knowledge graphs in EMRs-based medicine recommen-
dation system might enable the reinvented system to pro-
vide appropriate prescriptions for special patients, as well as
alerts of possible side effects and serious drug-drug interac-
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Figure 1: Left part is a medical knowledge graph with miss-
ing relationships. Right part is prescription records in EMRs,
and each edge indicates that a patient takes a medicine.
There is no relationship between medicines in EMRs.
tions (DDIs).
As shown in Figure1, linking EMRs and medical knowl-
edge graphs to generate a large and high-quality heteroge-
neous graph is a promising pathway for medicine recom-
mendations in a wider scope, but never easy. Specifically,
the newly designed system confronts with the following
challenges: 1. Computational Efficiency. Querying spe-
cialized medical entities and relationships based on conven-
tional graph-based algorithms have limitations in portabil-
ity and scalability. The computational complexity becomes
unfeasible when the heterogeneous graph reaches a very
large scale. 2. Data Incompleteness. The medical knowl-
edge graphs also follow the long-tail distribution as same
as other types of large-scale knowledge bases. Data incom-
pleteness is another serious problem existing among entities
and relationships in such a distribution. For example, since
the DDIs is not usually identified in the clinical trial phase,
there is a lack of significant DDIs in DrugBank which can-
not support a comprehensive precaution to the medication.
Last but not least, medicine recommendation suffers from
3. Cold Start. As conventional systems normally recom-
mend medicines based on the historical records, the pace of
recommendation changes cannot keep up with the frequent
updates of new therapies and treatments in medical prac-
tices. Little information on adverse reactions to the newly
updated medicines in historical EMRs or even in well-built
knowledge graphs makes the evidence-based recommenda-
tion model hardly support the new medicines as updated rec-
ommendations.
Taking all the challenges above into account, we pro-
pose a novel medicine recommendation framework based
on graph embedding techniques, inspired by the idea of link
prediction. We name our framework as Safe Medicine Rec-
ommendation (SMR) throughout this paper. The recommen-
dation process mainly includes:
1. A large heterogeneous graph is constructed from EMRs
and medical knowledge graphs, where the nodes are en-
tities (medicines, diseases, patients), and the edges (or
links) represent various relations between entities, such
as drug-drug interactions.
2. The different parts of the generated heterogeneous graph
(patient-medicine bipartite graph, patient-disease bipar-
tite graph, medicine knowledge graph, disease knowledge
graph) are embedded into a shared low-dimension space
based on graph-based embedding models. Afterward, a
joint learning algorithm is proposed to optimize the inte-
grated graph simultaneously.
3. Based on the learned embeddings, a new patient, repre-
sented by the vectors of his/her diagnoses, is modeled
as an entity in the disease-patient graph. Recommending
medicines for the patient is translated to predict links from
the patient to medicines.
The primary contributions of this work are summarized as
follows:
1. We have developed graph-based embedding models to
learn the effective representations of patients, diseases,
and medicines in a shared low-dimension space. The
representation of medicines enables the proposed frame-
work can even effectively recommend newly emerged
medicines for patients, which distinguishes most of the
existing works.
2. To recommend safe medicines for new patients, we pro-
pose a novel method for modeling a patient based on the
learned graph embeddings and make a safe recommenda-
tion by minimizing the potential adverse drug reactions.
3. We have conducted extensive experiments on large real-
world datasets (MIMIC-III, DrugBank, and ICD-9 ontol-
ogy) to evaluate the effectiveness of our framework. The
experimental results have shown that the proposed frame-
work outperforms all the compared methods.
4. To our best knowledge, we firstly propose a framework
to conduct Safe Medicine Recommendation (SMR) and
formulate it as a link prediction problem. The imple-
mentation generates a high-quality heterogeneous graph
in which relationships among patients, diseases, and
medicines can be unveiled in a wider scope.
The remainder of this paper is organized as follows: Sec-
tion 2 details our proposed framework SMR. Section 3 re-
ports the experimental results and Section 4 reviews related
work. Section 5 presents the conclusions and future work.
2 The Proposed Framework
In this section, we will first describe the notations and for-
mulate medicine recommendation problem, and then present
graph embedding models and how to use learned embed-
dings to recommend safe medicines for patients.
2.1 Problem Formulation
Before we focus on the medicine recommendation problem,
we first briefly introduce the important notations employed
in the remainder of this paper. Table 1 also summarizes
them.
The medical knowledge graph describes the medical en-
tities collected from the integrated sources, as well as rela-
tionships among these entities. For instance, a triple (gluco-
corticoid, adverse interaction, aspirin) indicates that there is
a relationship adverse interaction from glucocorticoid to as-
pirin in DrugBank. We define the medical knowledge graph
as follow.
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Figure 2: Overview of our framework. Patient-disease and patient-medicine graphs are all bipartite graphs, while disease and
medicine graphs are general graphs. Patient, disease, and medicine are encoded into a low dimensional metric by graph-based
methods. Diverse factors can be connected through patients.
Table 1: Notations.
Variable Interpretation
N ,R the set of entities and relations
(h, r, t) a triple in knowledge graph
h, t both are k dimensional vector embeddings
r a d dimensional relation embedding
Hr a k × d dimensional projection matrix
p,m, d a patient, medicine, disease
p, m, d a k dimensional vector of a patient,a medicine or a disease
Rk,Rd k and d dimensional latent space ofentities and relations
Definition 1 (Medical Knowledge Graph) The medical
knowledge graph G = (N ,R) is a set of triples in the form
(h, r, t), where N is a set of entities, R is a set of relations,
h, t ∈ N and r ∈ R.
To capture the co-relationships of patients, diseases, and
medicines in EMRs, we define the patient-disease, patient-
medicine bipartite graphs as follow.
Definition 2 (Patient-Medicine Bipartite Graph)
The patient-medicine bipartite graph is denoted as
Gpm = (P ∪M, Epm), where P is a set of patients andM
is a set of medicines. Epm is the set of edges. If a patient
pi takes a medicine mj , there will be an edge eij between
them, otherwise none. The weight wij of the edge between
patient pi and medicine mj is defined as the total times of
patient pi takes the medicine mj .
Definition 3 (Patient-Disease Bipartite Graph)
The patient-disease bipartite graph is denoted as
Gpd = (P ∪ D, Epd), where P is a set of patients
andD is a set of diseases. Epd is the set of edges. If a patient
pi is diagnosed with a disease dj , there will be an edge eij
between them, otherwise none. The weight wij is set to 1
when the edge eij exists.
Figure 2 illustrates a heterogeneous graph by construct-
ing patient-disease, patient-medicine bipartite graphs from
MIMIC-III, and linking them to medical knowledge graphs,
ICD-9 ontology, and DrugBank. Finally, we formally define
the safe medicine recommendation problem as follows.
PROBLEM 1 (Safe Medicine Recommendation) Given a
patient p and his/her diagnoses dataset Dp, recommending
safe medicines for each d ∈ Dp is predicting edges from p to
medicines datasetM. The output is a set of medicinesMp
with minimum drug-drug interactions.
2.2 Model Description and Optimization
In this section, we propose embedding learning approaches
to encode the heterogeneous graph in the latent space and its
optimization method.
Medical Knowledge Graph Embedding A medical
knowledge graph G = (N ,R) is a multi-relational graph,
in which entities N and relations R can be different types.
For a triple, (h, r, t) ∈ G, we use bold letters h, r, t
to denote the corresponding embedding representations of
h, r, t. Plenty of graph embedding methods has been pro-
posed to encode a multi-relational graphs into a continuous
vector space. Translation-based models (Bordes et al. 2013;
Wang et al. 2014; Lin et al. 2015) regard the relation r in
each (h, r, t) as a translation from h to t within the low di-
mensional space, i.e., h+ r− t, and perform much more
effectively and efficiently than conventional models. TransR
(Lin et al. 2015) is a state-of-the-art translation-based em-
bedding approach. It represents entities and relations in dis-
tinct vector space bridged by relation-specific matrices to get
better graph representations.
Consider the above reason, we set entities embeddings
h, t ∈ Rk and relations embeddings r ∈ Rd. And we set a
projection matrix Hr ∈ Rk×d, which projects entities from
entity space to relation space. We define the translations be-
tween entities and get the energy function z(h, r, t) as:
z(h, r, t) = b− ‖hHr + r− tHr‖L1/L2 (1)
where b is a bias constant.
Then, the conditional probability of a triple (h, r, t) is de-
fined as follows:
P (h|r, t) = exp{z(h, r, t)}∑
hˆ∈N exp{z(hˆ, r, t)}
(2)
and P (t|h, r), P (r|h, t) can be defined in the analogous
manner. We define the likelihood of observing a triple
(h, r, t) as:
L(h, r, t) = logP (h|r, t) + logP (t|h, r)
+ logP (r|h, t) (3)
We define an objective function by maximizing the condi-
tional likelihoods of existing triples in G:
LG =
∑
(h,r,t)∈G
L(h, r, t) (4)
Based on Eq.(4), the objective functions of medicine
and disease knowledge graph Gm = (Nm,Rm), Gd =
(Nd,Rd) can be defined respectively:
LGm =
∑
(hm,rm,tm)∈Gm
L(hm, rm, tm) (5)
LGd =
∑
(hd,rd,td)∈Gd
L(hd, rd, td) (6)
Bipartite Graph Embedding Different from the medical
knowledge graph, the patient-disease, patient-medicine are
bipartite graphs. A bipartite graph has only one single type
of relations, i.e., it is a homogeneous graph. For a homoge-
neous graph, LINE (Tang et al. 2015) model achieves the
state-of-the-art performance of encoding the entities into a
continuous vector space while preserving co-relations infor-
mation of the graph. Hence, we follow LINE and set pa-
tients, medicines, and diseases embeddings p,m,d ∈ Rk.
We present the process of encoding patient-medicine bipar-
tite graph as follow.
Given a patient-medicine bipartite graph Gpm = (P ∪
M, Epm). We first define the conditional probability of that
a patient pi in set P takes medicine mj in setM as follow:
P (mj |pi) = exp{z(pi,mj)}∑
mˆj∈Pi exp{z(pi, mˆj)}
(7)
where z(pi,mj) = mTj · pi, pi is the embedding vector
of the patient pi in P , and mj is the embedding vector of
medicine mj in M. Eq. (7) defines a conditional distribu-
tion P (·|pi) over all medicines inM. The empirical distri-
bution Pˆ (·|pi)is defined as Pˆ (mj |pi) = wijsumi , where wij is
the weight of the edge eij and sumi =
∑
j wij is the total
times that the patient pi takes medicines. We maximize the
following objective function:
LGpm = −
∑
pi∈P
λid(Pˆ (·|pi), P (·|pi)) (8)
where d(·, ·) is the distance between two distributions. In
this paper, we use KL-divergence to compute d(·, ·). As
sumi is different from patients, we use λi = sumi in the
objective function to represent the personalization of the pa-
tient pi in the graph. After omitting some constants, we have:
LGpm =
∑
eij∈Epm
wij log(P (mj |pi)) (9)
For the patient-disease bipartite graph, we can get the object
function LGpd in the analogous manner:
LGpd =
∑
eij∈Epd
wij log(P (dj |pi)) (10)
Optimization and Training To learn the medical knowl-
edge graph and bipartite graphs embeddings simultane-
ously, an intuitive approach is to collectively embed the four
graphs (patient-medicine bipartite graph, patient-disease bi-
partite graph, medicine knowledge graph, disease knowl-
edge graph) by maximizing the sum of the four logarithm
likelihood objective functions just as follow:
L(X) = LGm + LGd + LGpm + LGpd + γC(X) (11)
where X stands for the embeddings Rk, Rd of entities and
relations in the heterogeneous graph we construct, γ is a
hyper-parameter weighting the regularization factor C(X),
which is defined as follows:
C(X) =
∑
nm∈Nm
[||nm|| − 1]+ +
∑
nd∈Nd
[||nd|| − 1]+
+
∑
rm∈Rm
[||rm|| − 1]+ +
∑
rd∈Rd
[||rd|| − 1]+
+
∑
p∈P
[||p|| − 1]+ +
∑
d∈D
[||d|| − 1]+ +
∑
m∈M
[||m|| − 1]+
(12)
where [x]+ = max(0, x) denotes the positive part of x. The
regularization factor will normalize the embeddings during
learning. And we adopt the asynchronous stochastic gradi-
ent algorithm (ASGD) (Recht et al. 2011) to maximize the
transformed objective function.
Optimizing objective functions Eq. (5), Eq. (6), Eq. (9)
and Eq. (10) in Eq.(11) are computationally expensive, as
calculating them need to sum over the entire set of entities
and relations. To address this problem, we use the negative
sampling method (Mikolov et al. 2013) to transform the ob-
jective functions.
For Eq.(5) and Eq.(6), we should transform logP (t|h, r),
logP (r|h, t),logP (h|r, t) in Eq.(3). Taking P (t|h, r) as an
example, we maximize the following objective function in-
stead of it:
log σ(z(h, r, t))
+
C1∑
n=1
Eh˜n∼zneg({(h˜,r,t)})[σ(z(h˜n, r, t))]
(13)
where C1 is the number of negative examples, σ(x) =
1/(1 + exp(−x)) is the sigmoid function. {(h˜, r, t)} is the
invalid triple set, and zneg is a function randomly sampling
instances from {(h˜, r, t)}. When a positive triple (h, r, t) ∈
G is selected, to maximize Eq.(13), C1 negative triples are
constructed by sampling entities from an uniform distribu-
tion over N and replacing the head of (h, r, t). The trans-
formed objective of logP (r|h, t), logP (t|h, r) are maxi-
mized in the same manner, but for logP (r|h, t), the nega-
tive relations are sampled from a uniform distribution over
R to corrupt the positive relation r ∈ (h, r, t). We iteratively
select random mini-batch from the training set to learn em-
beddings until converge.
For Eq. (9), we also use the negative sampling method to
transform it to the following objective function:
log σ(z(pi,mj))
+
C2∑
n=1
Em˜n∼zneg(m˜)[log σ(z(pi, m˜n))]
(14)
where σ(x) = 1/(1 + exp(−x)) is the sigmoid function,
C2 is the number of negative edges. zneg(m˜) ∝ sum3/4m˜
according to the empirical setting of (Mikolov et al. 2013),
summ˜ is the total number of times that the medicine m˜ is
taken by patients. we can simplify Eq.(10) and maximize it
in the same way.
Finally, we can efficiently learn the embeddings of differ-
ent types of parts in the heterogeneous graph.
2.3 Safe Medicine Recommendation Process
In this section, we present how to recommend safe
medicines based on the learned embeddings and diagnoses
of a given patient. For an existing patient p, we use the
learned embedding p to predict new medicine recommenda-
tions. For a new given patient p, we first use diseases embed-
dings of p’s diagnoses to represent p, and then recommend
safe medicines for p, as shown in Figure 2,.
New Patient Model We aim to present a new patient p by
his/her diagnoses embeddings. We should consider the time
sequence of diseases that a patient is diagnosed, especially
for the patient with multiple diseases. Assume a patient p in
the hospital or on medication is associated with n ranked dis-
eases according to their timestamps in an increasing order.
Then, the patient embedding p can be encoded as follow:
p =
n∑
t=1
exp−t · dt (15)
where dt is the t-th embedding of disease dt.
Medicine Recommendation Given a query patient p with
the query disease d, i.e., q = (p, d), we first project disease
d and patient p into their latent space, and then select top-k
safe medicines1. More precisely, given a query q = (p, d),
for each medicine m which could be useful for p, we com-
pute its ranking score as in Eq. (16), and then select the
medicinem with the top-k highest ranking scores as the rec-
ommendation.
S(q,mn) = p
T ·mn−
n−1∑
o=1
‖mn + rinteration−mo‖L1/L2
(16)
1In MIMIC-III, patients in ICUs are sicker and usually need
more medicines for a diagnosis. We set k=3 in this paper.
Table 2: Entities and relations in the heterogeneous graph.
Entities Relations
#Disease 6,985 #Medicine-related 71,460
#Medicine 8,054 #Disease-related 170,579
#Patient 46,520 #Patient-Disease 489,923
#Medicine-related 305,642 #Patient-Medicine 975,647
where p is the representation of patient p and mn is the
n-th medicines to be considered from medicines M based
on the the already selected medicine m1, ...,mn−1.
3 Experiments and Evaluation
We attempt to demonstrate the effectiveness of our recom-
mendation method in this section, which is referred to as
SMR in this paper. In particular, we expect to answer “how
well does our method compare with the competing tech-
niques?” in Section 3.2. The results show that our recom-
mendation method significantly outperforms the three base-
lines. The detailed experimental settings of our evaluations
are described in Section 3.1.
3.1 Experimental Settings
Data Sets Our experiments are performed on the real
EMRs datasets, MIMIC-III (Johnson et al. 2016), and two
medical knowledge graphs, ICD-9 ontology (Schriml et al.
2011) and DrugBank (Law et al. 2014). These real datasets
are publicly available in different forms.
• MIMIC-III (Medical Information Mart for Intensive Care
III) collected bedside monitor trends, electronic medical
notes, laboratory test results, and waveforms from the
ICUs (Intensive Care Units) of Beth Israel Deaconess
Medical Center between 2001 and 2012. It contains dis-
tinct 46,520 patients, 650,987 diagnoses and 1,517,702
prescription records that associated with 6,985 distinct
diseases and 4,525 medicines.
• ICD-9 ontology2 (International classification of diseases-
version 9) contains 13,000 international standard codes of
diagnoses and the relationships between them.
• DrugBank is a bioinformatics/cheminformatics resource
which consists of medicine related entities. The medi-
cal knowledge graph version3 contains 8,054 medicines,
4,038 other related entities (e.g., protein or drug targets)
and 21 relationships.
Heterogeneous Graph Construction We connect MIMIC-
III, ICD-9 ontology, and DrugBank (medicine group 1) by
constructing the patient-medicine bipartite graph and the
patient-disease bipartite graph.
For the patient-disease bipartite graph, MIMIC-III pro-
vides ICD-9 codes for diagnoses, which implicitly the di-
agnoses of MIMIC-III can be linked to ICD-9 ontology by
string matching. For the patient-medicine bipartite graph,
2http://bioportal.bioontology.org/
ontologies/ICD9CM
3http://wifo5-03.informatik.uni-mannheim.
de/drugbank/
Table 3: Experiments on medicine group 1.
Prediction accuracy DDIs rate
Rule-based 0.3068 32.01%
K-Most frequent 0.3473 14.08%
LEAP 0.5582 1.66%
SMR 0.6113 0.17%
Table 4: Experiments on medicine group 2.
Prediction accuracy DDIs rate
Rule-based 0.2736 27.01%
K-Most frequent NA NA
LEAP NA NA
SMR 0.5214 2.01%
the prescriptions in MIMIC-III consist of the drug informa-
tion, e.g., the names, the duration, and the dosage. However,
various names to a single type of medicine in MIMIC-III ex-
ist due to some noisy words (20%, 50ml, glass bottle, etc.),
which becomes an obstacle to link medicine names to Drug-
Bank when directly applying to the string matching method.
We use an entity linking method (Wang et al. 2017) instead
to address this problem. Table 2 shows the statistic of the
heterogeneous graph we construct. The heterogeneous graph
will be used to learn low-dimension representations of enti-
ties and relations by the SMR framework. Afterward, we cat-
egorize the medicines in the heterogeneous graph into two
groups: 1). The first group consists of all 4,525 medicines
that are recorded in EMRs, and will be used as inputs of
the baseline methods. 2). The second group contains 3,529
medicines that haven’t been observed in EMRs, and will be
used as test data for cold start recommendation.
Baselines We compare our SMR with the following base-
lines:
• Rule-based method (Almirall et al. 2012) recommends
medicines based on mappings from existing medicine
categories to diseases in the MEDI database (Wei et al.
2013). For each disease, a drug is assigned to the patient
according to the mappings.
• K-Most frequent method is a basic baseline which re-
trieves the topK medicines that most frequently co-occur
with each disease as their recommendation. We setK = 3
in this paper.
• LEAP method (Zhang et al. 2017) uses a Multi-Instance
Multi-Label learning framework to train a predictive
model taking disease conditions as input features and
yielding multiple medicine labels as recommendations.
3.2 Evaluation Methods
To guarantee medicine recommendations generated by SMR
work effectively, we evaluate four indice, the prediction ac-
curacy, the ability to avoid adverse drug-drug interactions,
the experienced clinical doctor assessments, and the capac-
ity to process cold start problem. In all experiments, the ratio
of training to validation to test sets is 0.7:0.1:0.2. The hyper-
parameters was adjusted by a validation set.
Prediction Accuracy and DDIs Rate We utilize Jaccard
Coefficient to compare the similarity of the prescriptions
generated by SMR and the corresponding prescriptions writ-
ten by doctors. Given the recommendation medicines setMi
generated by SMR for a patient pi, Mˇi is the medicines set
prescribed by doctors in the data. The mean of Jaccard coef-
ficient is defined as follows,
Jaccard =
1
K
K∑
i
|Mi ∩ Mˇi|
|Mi ∪ Mˇi|
(17)
where K is the number of samples in a test set. Table 3
shows the accuracy of the baselines and SMR on medicine
group 1, the rule-based method performs the worst because
it is the only one provides a general recommendation for a
specific diagnosis and it is not able to endow personalized
recommendations, especially for the patients with multiple
diseases. The frequency of each medicine-disease pair re-
mains high in ICUs. Hence, recommendations based on fre-
quency,K-Most frequent method, also work deficiently. Our
method SMR outperforms LEAP by 1.49% because more
accurate medical facts are involved in medical knowledge
graphs rather than the prescription information in EMRs.
We extract all adverse drug-drug interactions (DDIs) from
DrugBank to evaluate whether medicine recommendations
embrace unsafe DDIs. Table 3 shows the percentages of
different medicine recommendations consisting of adverse
DDIs. The result indicates that SMR can recommend most
harmless medicines for patients as its drug interaction rate
is the lowest. The rule-based method and K-Most frequent
method select medicines by a greedy strategy only regard-
less of specific adverse DDIs. For the rarely used medicines
and unknown DDIs in EMRs, SMR is more reliable than
LEAP. The reason is that SMR can predict each patient-
medicine link and compute potential hidden DDIs by the
learned embeddings of medical knowledge graphs.
Cold Start We evaluate the ability of baselines and SMR
in addressing cold start medicine recommendations on the
medicine group 2. K-Most frequent method and LEAP are
not applicable (NA) on recommending new medicines in
the cold start scenario. Since our SMR process can present
new medicines by the learned vector representations of used
medicines, the potential patient-medicine links between cold
start medicines and patients will be captured correspond-
ingly. In other words, SMR can leverage not only the patient-
medicine links in EMRs but also the medical knowledge
graphs when recommending cold start medicines.
Clinical Assessment We invited three experienced clini-
cal experts to evaluate the effectiveness of the medicine rec-
ommendations by scoring on a 6-point scale: 5 correspond-
ing to completely cover all diagnoses without DDIs; 4 to
partially (at least 50%) diagnoses include without DDIs; 3
to completely cover all diagnoses with DDIs; 2 to less than
50% diagnoses without DDIs; 1 to partially (at least 50%)
diagnoses covered with DDIs; 0 to less than 50% diagnoses
Table 5: Examples of medicine recommendations generated by Baselines and SMR.
Diagnosis Methods Medicine Recommendations
Sepsis
Acute respiratry failure
Hypertension
Rule-based Teicoplanin, Metoprolol
K-Most frequent Vancomycin, Furosemide, Metoprolol, Insulin
LEAP Vancomycin, Furosemide, Metoprolol Tartrate
SMR Vancomycin, Furosemide, Amlodipine, Norepinephrine, Acetaminophen
Type 2 diabetes
Rheumatoid arthritis
Hypertension
Hyperlipidemia
Rule-based Gliclazide, Phenylbutazone, Sulfasalazine, Fenofibrate
K-Most frequent Furosemide, Tolbutamide, Phenylbutazone, Metoprolol, Insulin, Acetaminophen
LEAP Metformin, Amethopterin, Amiloride/HCTZ, Fenofibrate
SMR Metformin, Insulin, Acetaminophen, Nifedipine, Fenofibrate
SMR LEAP K-Most frequent Rule-based
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Figure 3: Clinical Assessment.
with DDIs. The average score of three experts is used as the
final clinical assessment score for each recommendation, as
shown in Figure 3.
Case Study In table 5 we illustrate two events of medicine
recommendations on medicine group 1 for patients associ-
ated with multiple types of diseases. SMR is qualified to suc-
ceed in all these two cases when comparing it against other
baselines. For the first patient, SMR recommended a set of
medicines with 100% coverage, with Vancomycin for Sep-
sis, Norepinephrine, Acetaminophen for respiratry failure,
Furosemide and Amlodipine for Hypertension. In contrast,
other baselines are not capable of make an adequate consid-
eration. The rule-based method adopted Teicoplanin, target-
ing Sepsis only and not appropriate. The K-Most frequent
method and LEAP only selected Vancomycin for Sepsis and
other medicines for Hypertension. For the second patient,
SMR recommends more suitable medicines than LEAP and
Rule-based method, i.e., Metformin and Insulin for Type
2 diabetes, Acetaminophen to release Rheumatoid arthritis,
Nifedipine for Hypertension, and Fenofibrate for Hyperlipi-
demia. There is an adverse DDI among the medicines rec-
ommended by the K-Most frequent method. Tolbutamide
and Phenylbutazone can lead to harmful, potentially fatal ef-
fects when taken together. This case also indicates SMR can
avoid the adverse DDIs when recommending medicines.
4 Related Work
In this section, we discuss related work, including medicine
recommendation and medical knowledge graphs.
Medicine Recommendation As introduced in Section 1,
two types of methods, rule-based protocols (Chen et al.
2016; Gunlicks-Stoessel et al. 2016; Almirall et al. 2012),
and supervised-learning-based methods (Zhang et al. 2017;
Zhang et al. 2014), are currently utilizing EMRs to recom-
mending medicines. Ideally, medicine recommendation sys-
tems aim to tailor treatment to the individual characteris-
tics of each patient (Fernald et al. 2011). Hence, medicine
recommendation has also received attention recently in ge-
netics/genomics research fields. There are already existing
medicine recommendation systems (Rosen-Zvi et al. 2008;
Bennett and Hauser 2013) by leveraging genetics/genomics
information of patients in current practice, such information
is not yet widely available in everyday clinical practice, and
is insufficient since it only addresses one of many factors
affecting response to medication.
Medical Knowledge Graphs Recent evaluation efforts
on knowledge graphs have focused on automatic knowl-
edge base population and completion. Some knowledge
graphs have also been constructed from huge volumes
of medical databases over the last years, such as (Ernst,
Siu, and Weikum 2015), Bio2RDF(Dumontier et al. 2014),
and Chem2Bio2RDF(Chen et al. 2010). Medical knowl-
edge graphs contain an abundance of basic medical facts
of medicines and diseases and provide a pathway for med-
ical discovery and applications, such as effective medicine
recommendations. Unfortunately, such medical knowledge
graphs suffer from serious data incomplete problem, which
impedes its application in the field of clinical medicine.
5 Conclusion and Future Work
In this paper, we propose a novel framework SMR to rec-
ommend safe medicines for patients, especially for the pa-
tients with multiple diseases. SMR first constructs a high-
quality heterogeneous graph by bridging EMRs (MIMIC-
III) and medical knowledge graphs (ICD-9 ontology and
DrugBank). Then, SMR jointly embeds diseases, medicines,
patients, and their corresponding relations into a shared
lower dimensional space. Finally, SMR uses the embeddings
to decompose the medicine recommendation into a linked
prediction process while considering the patient’s diagnoses
and adverse drug reactions. Extensive experiments on real
world datasets are conducted and demonstrate the effective-
ness of SMR. In future work, we will improve the linking
accuracy by considering more information of patients, such
as the clinical outcomes and demographics.
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